BridgeBio Pharma
BBIO
66.50
-0.46
-0.69%
BridgeBio Pharma
US · BBIO
#1254 by market cap
Listed 2019
66.50
-0.46
-0.69%
Live - 5344 symbols - heartbeat 8s ago
· 2026-10-08 05:32
Pre-market
66.30
-0.30%
After-hours
65.99
-0.77%
Overnight
66.50
0.00%
- Market cap
- 13.00B
- P/E (TTM)i
- -18.68
- P/Bi
- -5.17
- EPSi
- -3.78
- Div yieldi
- 0.00%
- 52W posi
- 34%
Reader sentiment
Are you bullish or bearish on BBIO?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 17 analysts
Buy
Avg price target
111.44 +67.6%
Price target rangecurrent 66.50
Low94.00
Avg111.44
High157.00
Buy 94%
Hold 6%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-30 | Barclays | -- | BUY | 157.00 |
| 2026-09-24 | TD Cowen | -- | BUY | 110.00 |
| 2026-09-14 | Evercore | -- | BUY | 130.00 |
| 2026-09-10 | H.C. Wainwright | -- | BUY | 120.00 |
| 2026-09-02 | H.C. Wainwright | -- | BUY | 120.00 |
| 2026-08-31 | Mizuho Securities | -- | BUY | 110.00 |
| 2026-08-31 | Piper Sandler | -- | BUY | 115.00 |
| 2026-08-31 | Jefferies | -- | BUY | 110.00 |
| 2026-08-31 | Barclays | -- | BUY | 157.00 |
| 2026-08-29 | Cantor Fitzgerald | -- | BUY | 110.00 |
| 2026-08-14 | RBC Capital | -- | BUY | 100.00 |
| 2026-08-12 | CCORF | -- | BUY | 106.00 |
| 2026-08-12 | Truist Financial | -- | BUY | 107.00 |
| 2026-08-12 | Citi | -- | HOLD | 94.00 |
| 2026-08-12 | Barclays | -- | BUY | 157.00 |
| 2026-08-12 | J.P. Morgan | -- | BUY | 111.00 |
| 2026-08-11 | TD Cowen | -- | BUY | 110.00 |
| 2026-08-11 | Wells Fargo | -- | BUY | 102.00 |
| 2026-08-11 | William Blair | -- | BUY | -- |
| 2026-08-11 | Piper Sandler | -- | BUY | 115.00 |
| 2026-08-11 | BofA Securities | -- | BUY | 104.00 |
| 2026-08-11 | Truist Financial | -- | BUY | -- |
| 2026-08-11 | Morgan Stanley | -- | BUY | 97.00 |
| 2026-08-11 | Jefferies | -- | BUY | 110.00 |
| 2026-08-10 | TD Cowen | -- | BUY | 110.00 |
Quant vs Street three independent views, side by side
StockVane factor grade
D+
Momentum strategy signal
Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-10 | After close | ±7.22% | -1.15% (in line) |
| 2026/Q1 | 2026-05-07 | After close | ±7.23% | -0.09% (in line) |
| 2025/Q4 | 2026-02-24 | After close | ±11.04% | -2.59% (in line) |
| 2025/Q3 | 2025-10-29 | After close | ±10.92% | -4.88% (in line) |
| 2025/Q2 | 2025-08-05 | After close | ±14.51% | -8.94% (in line) |
| 2025/Q1 | 2025-04-29 | After close | ±12.86% | +5.33% (in line) |
| 2024/Q4 | 2025-02-20 | -- | -- | +1.42% |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 05:32:13 · For reference only, not investment advice and not tailored to your situation.